Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Iscalimab extension study in Sjögren's Syndrome
NCT04541589Phase 2Completed
- Sponsor
- Novartis
- Start
- Jan 2021
- Primary completion
- Aug 2024
- Modality
- Monoclonal Antibodies
- Countries
- 23
01
Overview
Phase 2, open-label trial of iscalimab in Sjögren's syndrome (2 arms), sponsored by Novartis. Primary endpoint: Treatment-emergent Adverse Events at 60 weeks. Started Jan 2021; status: completed.
02
Drugs
iscalimab
03
Conditions
Sjögren's syndrome
Beyond the preview
Go deeper on NCT04541589.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04541589.